Navigation Links
Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
Date:11/5/2009

n Time. The live event will be available from Trubion's website at http://investors.trubion.com, or by calling (703) 639-1156 or (866) 238-0637. A replay of the discussion will be available beginning at 8 p.m. Eastern Time from Trubion's website or by calling (703) 925-2533 or (888) 266-2081 and entering 1408250. The telephone replay will be available until midnight, Nov. 11, 2009.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The Company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP, therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the Company's Pfizer collaboration. Trubion's product pipeline also includes TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies developed under the company's Facet collaboration. In addition to Trubion's current clinical stage product pipeline, the Company is also developing its multi-specific SCORPION technology, both for targeting cell-surface molecules like CD79b and HLA-DR, as well simultaneously neutralizing soluble ligands like TNF and IL-6. More information is available in the investors section of Trubion's website: http://investors.trubion.com/index.cfm.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Trubion Announces Upcoming Presentation at 8th Annual BIO Investor Forum
2. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
3. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
4. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
5. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
6. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
9. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
10. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
11. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:7/10/2014)... New York City, NY (PRWEB) July 10, 2014 ... to the life sciences industry, has launched a new ... mobile responsiveness, as well as increased access to the ... “The new cbpartners.com provides an ideal platform to showcase ... global health access issues,” says CBPartners’ Chief Executive Officer, ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 ... the latest results of the 4th “Trending in ... suite model. , Every day multinational corporations ... contracts, expense forms etc. To meet this challenge, ... (S2P) suites which can be defined as a ...
(Date:7/10/2014)... -- Adults with dyslexia are more likely to report ... than people who don,t have the learning disorder, according ... up to 10 percent of people, causes problems with ... adults with this condition said they suffered physical abuse ... without dyslexia. "Even after accounting for age, race, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... use of calorie information on menus, if it,s available, to ... U.S. study. Women in particular review the menu labeling, ... with the U.S. Centers for Disease Control and Prevention. ... to help choose their meal, compared with just under half ...
(Date:7/10/2014)... the amount of alcoholic beverages consumed, even for ... reduced risk of coronary heart disease, lower body ... a new multi-center study published in The ... of Medicine at the University of Pennsylvania. The ... suggest that consuming light-to-moderate amounts of alcohol (0.6-0.8 ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 2Health News:‘Source-to-Pay’ e-Procurement Is Real Performance Driver for Purchasing Departments 3Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 2Health News:60 Percent of Diners Use Calorie Labeling When Posted: CDC 3Health News:New study shows drinking alcohol provides no heart health benefit 2
... March 26 The statement below is attributable ... Association. This statement is being issued in response to ... England Journal of Medicine about prostate-specific antigen ... great interest the coverage surrounding the two studies about ...
... Percent of Surveyed MCO Pharmacy Directors Say They ... Idiopathic Arthritis and Pediatric Crohn,s Disease, According to ... 26 Decision Resources, one of the world,s ... healthcare issues, finds that 30 percent of surveyed ...
... radicals, researchers say , , THURSDAY, March 26 (HealthDay ... children,s lung growth and function, as well as ... University of Southern California researchers. , "Many factors ... variation and environmental exposures such as tobacco smoke ...
... (ASCTA) is formed in response to the Food and Drug Administration,s ... body are drugs, a position the ASCTA opposes. This physician ... adult stem cell therapy to their patients more quickly. , ... ...
... Strategic Cost Management Expertise with Hospitals Nationwide to Help ... An exclusive group of hospital CEOs from ... to Texas, and California to the Carolinas, will convene ... summit to address the implications of the economic stimulus ...
... March 26 Birner Dental Management Services, Inc. ... of PERFECT TEETH dental practices, ... Total dental group practice revenue decreased $371,000, or .6%, ... to $34.5 million. The Company,s earnings before interest, taxes, ...
Cached Medicine News:Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 2Health News:American Urological Association Statement in Support of Prostate-Specific Antigen Testing 3Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 2Health News:As a Result of the FDA Investigation Into TNF-Alpha Inhibitors, 30 Percent of Surveyed Rheumatologists Have Altered Their Prescription Patterns for Juvenile Idiopathic Arthritis 3Health News:Genes May Boost Harm to Kids From Secondhand Smoke 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 2Health News:Physician Group Opposes FDA's Position on Adult Stem Cells 3Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 2Health News:Healthcare CEO Summit Addressing Strategic Implications of Economic Stimulus Package to be Hosted by InfoLogix 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 2Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 3Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 4Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 5Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 6Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 7Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 8Health News:Birner Dental Management Services, Inc. Announces Earnings for Year End and Fourth Quarter 2008 9
... endoscope is the first Video ... instrument incorporates a 2.0mm instrument ... insertion tube. The slim size ... easy introduction even through areas ...
... Used for temporary internal drainage from ... Supplied sterile in peel-open packages. Intended ... is advised; C-Flex® and Sof-Flex® stents ... six (6) months; silicone stents must ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
... Double Pigtail Ureteral Stents have an ... maximizes migration. They also feature unique ... cost savings. Each Classic Double PigTail ... Double PigTail Ureteral Stent with attached ...
Medicine Products: